Global Arena Holding Inc. (OTCMKTS:GAHC) Powering Higher But For How Long?

Global Arena Holding Inc. (OTCMKTS:GAHC)

Global Arena Holding Inc. (OTCMKTS:GAHC) impressive run in the market continued in Monday’s trading session in line with the rally being experienced in the Bitcoin space. The stock was up by 13.3% to end the day at $0.0357 a share. However, the rally came as a surprise given that the company is fresh from posting a wider than expected net loss for the three months ended June 30, 2017.

Global Arena Stock Chart:

Global Arena Holding Inc. (OTCMKTS:GAHC)
One month stock price chart for GAHC

Global Arena Stock Performance

Shares of Global Arena Holding Inc. (OTCMKTS:GAHC) were one of the biggest gainers in the second quarter after rallying from lows of $0.01 a share to highs of $0.063 a share. The rally came as Bitcoin continued to clock higher highs in line with growing demand for the cryptocurrency. The stock is currently trading in a tight $0.03-$0.05 trading range waiting to see if the momentum is strong enough to push the stock beyond its 52-week high of $0.07 a share.

The fact that the stock rallied even on the company posting wider than expected net loss shows that investors are betting on Global Arena as a Bitcoin play.

Bitcoin Factor

Global Arena Holding Inc. (OTCMKTS:GAHC) operates under two subsidiaries. GAHI Acquisition Corp provides the company with exposure to crypto type business through the application of blockchain technology to various sectors such as tech and finance.

Global Arena Holding Inc. (OTCMKTS:GAHC) also uses blockchain technology to secure voting records through its GES subsidiary. The company has so far managed elections in five continents and in the process processed 3.7 billion votes. It has also started to work on a new voting program that will allow its subsidiary GES to conduct more elections

How long the company will continue to power high in the charts depends on the performance of Bitcoin going forward. The performance of the cryptocurrency should continue having a ripple effect not only to Global Arena Holding Inc. (OTCMKTS:GAHC) but all stocks with exposure to the Blockchain technology.

Separately, Global Arena Holding Inc. (OTCMKTS:GAHC) says it generated a net loss of $5.3 million for the three months ended June 30, 2017, compared to a net loss of $2.7 million for the corresponding period last year. Operating expenses in the quarter doubled to $5.3 million from $2.6 million reported a year earlier. The company reported revenues of $275,300 shares compared to revenues of $322, 502 reported last year.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $GAHC and receive breaking news on other hot stocks by signing up for our free newsletter!

Neothetics Inc (NASDAQ:NEOT) Tumbles To 52-Week Low

Neothetics Inc (NASDAQ:NEOT)

Shares of Neothetics Inc (NASDAQ:NEOT) tumbled 18.04% after the company reported second quarter financial results that fell short of Wall Street expectations. The selloff came on the clinical stage pharmaceutical company reporting a wider than expected second quarter net loss of (-$2.8) million compared to (-$2.7) million reported a year ago.

Neothetics Inc (NASDAQ:NEOT)
One month NEOT stock price chart

Stock Performance

Thursday’s sell off pushed Neothetics Inc (NASDAQ:NEOT) on the brink of its 52 week low of $0.30 as it continues to trade in a tight $0.30-$0.46 trading range. Neothetics sentiments turned sour early last month after the stock gapped lower from highs of $2.3 a share to current lows of $0.37 a share.

The stock continues to trade below its 20 days moving average having also tanked more than 60% below its 50-day moving average. The stock is currently trading at all-time lows having tanked from highs of $2.6 a share as of June.

The clinical stage pharmaceutical develops therapeutics for fat reduction and body contouring. Its lead product is LIPO-202, an injectable formulation for the reduction of localized fat deposits under the chin as well as for the deduction of central abdominal reduction.

The board of directors recently approved plans to initiate acquisitions as well as partnerships as part of an effort that seeks to expand Neothetics Inc. (NASDAQ:NEOT) footprint into new areas of growth. Pursuit of strategic alliance is also geared towards discovering and maximizing shareholder value. The company has already engaged the services of Oppenheimer and Co as its financial advisor for the new initiative.

Neothetics Inc (NASDAQ:NEOT) has also announced plans to streamline its operations as it seeks to preserve capital and cash resources. Plans are underway to trim the company’s workforce from six to two as the firm seeks to reduce its wage bill.

Q2 Earnings

The cost reduction drive follows an increase in research and development expenses in the second quarter to $1.6 million from $1.4 million. However, for the six months ended June 30, 2016, R&D expenditure dropped to $3.1 million from $4.7 million a year earlier. Neothetics attributes the decline to completion of a majority of close out activities for AbCONTOUR1 and AbCONTOUR2 U.S. Phase 3 clinical trials

Neothetics Inc (NASDAQ:NEOT) General and administrative expenses soared to $1.3 million from $1.1 million a year earlier. However, for the six months ended June 30, 2017, total general administrative expenses dropped to $2.7 million from $3.6 million a year earlier. The company attributes the decline to reduced personnel expenses.

Neothetics Inc. (NASDAQ:NEOT) exited the second quarter with cash and cash equivalent of $7.6 million compared to $11.5 million as of December 31, 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $NEOT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Dextera Surgical Inc (NASDAQ:DXTR) Stock Gives Up Gains

Dextera Surgical Inc (NASDAQ:DXTR)

Shares of Dextera Surgical Inc (NASDAQ:DXTR) stock tumbled 12.74% after the company reported a net loss of $3.1 Million for the fourth quarter ended June 30, 2017. News of the net loss comes weeks after the company initiated a temporary shipping hold on its flagship MicroCutter 5/80 Stapler and reload cartridges.

Wednesday’s sell-off plunged Dextera Surgical Inc (NASDAQ:DXTR) stock  close to its 52-week low of $0.17 a share. The company’s stock is currently trading in a tight $0.24 to $0.25 trading range inside a strong downtrend.

Dextera Stock Price Chart:

Dextera Surgical Inc (NASDAQ:DXTR)
One month stock price chart for DXTR

Dextera Q4 Earnings Report

Dextera Surgical Inc (NASDAQ:DXTR) is a medical device company that develops proprietary stapling devices for minimally invasive surgical procedures. MicroCutter 5/80 is the company’s lead product used for thoracic pediatric colorectal and general surgeries. The company also develops anastomotic systems for use by cardiac surgeons.

The medical device company generated sales of $1 million in the fourth quarter compared to $0.7 million for the corresponding period last year. MicroCutter sales in the quarter stood at $359,000 down from $516,000 as of the third quarter. The company attributes the decline to a backorder for the blue reload cartridges and shipping hold at the end of the quarter.

“We have identified and addressed the cause for the premature lock out of the MicroCutter 5/80 surgical staplers announced on July 6th, and after extensive in-house testing of the modification, we resumed shipping to our customers,” said Julian Nikolchev, president, and CEO of Dextera Surgical Inc.

Dextera Surgical Inc (NASDAQ:DXTR) exited the fourth quarter with cash and cash equivalent of $6 million compared to $2.5 million as of the end of the third quarter.

Corporate Highlights

During the quarter, Dextera Surgical Inc (NASDAQ:DXTR) executed a strategic partnership with B Braun for the distribution of the MicroCutter 5/80 Stapler. Under the terms of the agreement, B Braun Surgical will distribute the stapler directly and through indirect sales representatives in Spain.

In a bid to meet growing demand for the MicroCutter 5/80, Dextera Surgical is in the process of optimizing its supply chain as it also works on increasing production capacity to 120 MicroCutter by the end of the year. There are also plans to increase the device’s indications to expand its usage into liver pancreas Kidney and spleen surgery.

Dextera Surgical Inc (NASDAQ:DXTR) has also entered into a co-development project with Intuitive Surgical for the development of a new robotic stapler based on the current MicroCutter technology

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DXTR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Is GoPro Inc (NASDAQ:GPRO)’s Turnaround Strategy Finally Paying Off?

GoPro Inc (NASDAQ:GPRO)

GoPro Inc (NASDAQ:GPRO) was up by 1.73% in Monday’s trading session after Morgan Stanley analyst, Yuuji Anderson, upgraded the stock to an Equal Weight. The upgrade came on growing confidence that cost cuts and new video editing functions are paying off. The analyst also expects new software to help trigger an upgrade cycle of the company’s old devices.

GoPro Inc (NASDAQ:GPRO)
One month daily candlebar chart for $GRPO

Stock Performance

Shares of GoPro Inc (NASDAQ:GPRO) have stabilized this year amidst talk that the company is a turnaround play. The stock continues to trade between $7.50 and $9 a share after plummeting from record highs of $90 a share as of 2014. Cost cuts have come into play ever since the company lost $200 million last year. The camera maker has also raised cash through convertible debt in a bid to stay afloat.

Optimism that GoPro Inc (NASDAQ:GPRO) continues to soar on the belief that the forthcoming Fusion 360-degree camera will be a success. The company has already shipped some units of the camera as part of a pilot program. The response so far has been positive. While the camera is not expected to be enough to save the stock on its own, an intriguing go-to-market strategy could help revitalize the company’s prospects.

GoPro Turnaround Strategy

GoPro Inc (NASDAQ:GPRO) has already received 20,000 applications from content creators. The company is banking that such content will help consumers better understand the capabilities of the Fusion camera.

The company is also paying close watch to software updates as it seeks to differentiate its software platform versus their competitors. The launch of the QuickStories feature is designed to make it easy for users to get edited footage off their cameras. The software, coupled with smartphone connectivity, is a key pillar of GoPro Inc (NASDAQ:GPRO) strategy going forward.

“[…] What happens when that business fixes that problem and now has a solution that’s very easy for the consumer to be successful with? We believe that can have a dramatic impact on our company because it’s going to have a dramatic impact on consumers,” said Nick Woodman, GoPro CEO.

Helped by the launch of the Hero5 camera. sales of the company’s products in the first quarter rose 19%. Narrowing of the product line to just four consumer devices has helped the company simplify its marketing strategy and drive efficiencies.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $GPRO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) Hit by FDA Decision

IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI)

IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) shares are down over 40% after independent advisers to the U.S. Food and Drug Administration (FDA) failed to support the approval of Intellipharmaceutics’ long-acting opioid painkiller, Rexista. On Tuesday, IPCI shares closed at $2.49 and gapped down Wednesday morning to open at $1.80 then reached a low of $1.31. At 10:45 AM EST IPCI shares were trading around $1.50 with over two million shares traded. The 30-day, daily volume average is just over 242,000. Today’s price drop easily established a new 52-week low which had been at $1.58.

IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI)
10-day, 15 minute candle graph for $IPCI

IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) is a Canadian pharmaceutical company that develops and manufactures proprietary and generic controlled-release and targeted-release oral solid dosage drugs. IntelliPharmaCeutics patented Hypermatrix™ technology is a drug delivery platform that can be applied to the development of existing and new pharmaceuticals. Based on this technology platform, Intellipharmaceutics has developed several drug delivery systems and a pipeline of products (some of which have received FDA approval) and product candidates in various stages of development, including Abbreviated New Drug Applications (“ANDAs”) filed with the FDA (and one Abbreviated New Drug Submission filed with Health Canada) in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain.

It appears, however that the lack of support from the FDA advisors is not a death knell for Rexista. The committee expressed a desire to review additional safety and efficacy data. Accordingly, Intellipharmaceutics intends to conduct Category 3 abuse potential studies to provide data that the company believes supports the abuse-deterrent properties of Rexista. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) has an FDA approved protocol for a human abuse potential study for the intranasal route of abuse, which it plans on beginning within weeks.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IPCI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Will Deal Reverse Fortunes for FuelCell Energy Inc (NASDAQ:FCEL)?

FuelCell Energy Inc (NASDAQ:FCEL)

FuelCell Energy Inc (NASDAQ:FCEL) shares gained almost 7.5% on news of an award by PSEG Long Island for a 39.8 megawatts fuel cell project under the Fuel Cell Resources Feed-in Tariff. The Long Island Power Authority (LIPA) will, under the PSEG program, purchase power from the fuel cell projects under 20-year power purchase agreements. FuelCell Energy Inc (NASDAQ:FCEL) will install, operate and maintain the fuel cell power plants.

NASDAQ:FCEL
Six Month Daily Candle Bar Graph for $FCEL

FuelCell Energy Inc (NASDAQ:FCEL), headquartered in Danbury, CN, aims to develop clean, efficient, and affordable fuel cell solutions. FuelCell provides comprehensive turn-key solutions for their customers and includes everything from the design and installation of a project to the long-term operation and maintenance of the fuel cell system.

The local municipality of Brookhaven will benefit from incremental revenue as three vacant commercial parcels of land are converted to revenue producing sites. Next steps in project development include working with the utility on the interconnection agreements, power purchase agreements, and finalizing site engineering. The SureSource 4000 is the largest power plant in FuelCell Energy Inc (NASDAQ:FCEL)’s product portfolio, generating 3.7 megawatts of clean power with leading electrical efficiency of approximately 60 percent. This enhanced-efficiency fuel cell system is designed for applications focused on clean and affordable power driven by the economics of high system electrical efficiency rather than thermal efficiency.

FCEL shares have done well for the past month, generating gains of over 22% but for the year are down over 70%. FCEL shares have been heavily diluted since 2012 when 13.79 million shares were outstanding. Each year the number of outstanding shares increased and by 2016 the number stood at 29.77 million. In the meantime, sales have been decreasing. In 2013 the company posted $187.7 million in sales but only $108.3 million in 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $FCEL and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Regen BioPharma Inc. (OTCMKTS:RGBP) Discovers New Autoimmune Compounds

Regen BioPharma Inc. (OTCMKTS:RGBP)

Shares of Regen BioPharma Inc. (OTCMKTS:RGBP) plunged 17.70% in Tuesday’s trading session to end the day at $0.0279 a share. The selloff came on the company reporting progress on the development of small molecules that activate and inhibit NR2F6, a cancer stem cell differentiation.

Regen BioPharma NR2F6 Discovery

Regen BioPharma Inc. (OTCMKTS:RGBP) is a biotechnology firm specializing in the development of regenerative medicine in the stem cell space. The company also develops treatments for Aplastic Anemia and gene silencing therapy for treating various types of cancers. Some of the company’s lead products under development include HemaXellerate for the treatment of damaged bone marrow, and dCellVax a cellular therapy for improving immune system through gene silencing.

A discovery of a new dynamic compound for modulating the NR2F6 checkpoint is the company’s latest achievement on its push to come up with new regenerative treatments. The NR256 program seeks to come up with antagonists of NR2F6 in an effort to trigger the cancer killing potential of patients’ immune system.

Regen BioPharma Inc. (OTCMKTS:RGBP) newly discovered compound that has the potential to treat autoimmune diseases with virtually no toxicity. The company carried out tests on three identified agonists – all of which proved to be reliable in inhibiting cytokine production in stimulated immune cells.

“The Company believes that these recent 3 compound groups just need some fine-tuning to be the basis for our autoimmune therapies. Additionally, using this information, we are now able to ramp up our inhibitor program which focuses on anti-cancer drugs,” said David Koo, Regen BioPharma Inc. (OTCMKTS:RGBP) CEO.

The three compounds were identified from the company’s patented screening methodology and unique chemical libraries. Tests on the structures of the three compounds has resulted in one particular series becoming the favored activator for triggering the autoimmune system.

Regen BioPharma Inc. (OTCMKTS:RGBP) has already carried out tests on over 250 analogues of the favored structure from which it has discovered clear relationships on the structure ability to trigger NR2F6.

Q1 Earnings

Separately, Regen BioPharma Inc. (OTCMKTS:RGBP) did not report any revenues for the first three months of the year. Net loss on the other hand soared to highs of (-$1.39) million compared to a net loss of (-$726,064) reported last year. The company’s net loss for the first six months ended March 31, 2017 soared to $1.96 million compared to $1.42 million for the corresponding period last year.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RGBP and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.